Thera-SAbDab

DALOTUZUMAB

>   Structural Summary
TherapeuticDalotuzumab
TargetIGF1R
Heavy ChainQVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSS
Light ChainDIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2009
INN Year Recommended2010
Companies InvolvedPierre Fabre, Merck & Co
Conditions Approvedna
Conditions ActiveBreast cancer, Colorectal cancer, Pancreatic cancer
Conditions DiscontinuedMultiple myeloma, Neuroendocrine tumours, Non-small cell lung cancer, Solid tumours
NotesJain paper: "Entries in WHO-INN documents (PL102 and RL64) have errors"

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]